Bristol-Myers Squibb Company
NYSE: BMY
$59.18
+$0.31 (+0.5%)
Real Time Data Delayed 15 Min.
BMY Articles
Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better than analysts expected, but worries persist that the company will be hit...
Published:
Last Updated:
Drug and medical stocks are not generally thought of as stocks hitting 52-week highs by the investing public. So what about when a company decides to unlock shareholder value by breaking itself...
Published:
Last Updated:
Sales for the big pharmaceutical companies are expected to be hit by pricing pressure in Europe, a lack of urgent new on the coming flu season, lower rates of prescription writing, and more...
Published:
Last Updated:
With fears of a new economic downturn, investors have become concerned about sales and profits of large companies. But there are companies that have already proven themselves in the recent recession....
Published:
These are some of this Thursday’s top analyst upgrades, downgrades, and initiations seen having an impact from Wall Street research calls. Amerisafe, Inc. (NASDAQ: AMSF) named Bear of the Day at...
Published:
Last Updated:
These are some of this Monday’s top analyst upgrades, downgrades, and initiations seen having an impact from Wall Street research calls. Applied Materials Inc. (NASDAQ: AMAT) Cut to Sell at Goldman...
Published:
Last Updated:
A new heart drug aimed a reducing the risk of strokes has outperformed the current drug of choice, warfarin, in a study that shows it lowers risk from a type of arrhythmia by 21% and lowers bleeding...
Published:
Last Updated:
LG Display (NYSE: LPL) cuts capital expenditures as demand for LCD screens is hurt by tablet PC sales. (Reuters) Samsung to delay its tablet launch in the U.S. because of IP lawsuits from Apple...
Published:
Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability. One way to make up for the loss is to get US Food & Drug...
Published:
Many drug companies face a what is called a patent cliff ahead, where the Big Pharma players will have key drugs go off-patent and there will be new generic competition. While this is a challenge...
Published:
We may have just witnessed an oversold bounce in the stock market, or we may be in for more days of recovery. The markets are flirting with six weeks of negative performance and one day is not...
Published:
Last Updated:
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Wednesday morning. Aixtron SE (NASDAQ: AIXG) Cut to Sell at Canaccord Genuity....
Published:
Last Updated:
The fight against melanoma just got a new weapon after a drug called Yervoy, or ipilimumab, was given FDA approval for late-stage metastatic melanoma. The approval is a win for Bristol-Myers...
Published:
Last Updated:
Earnings season may still be in force, but we are looking for the coming week’s top coming events that could have a large impact on shares on Monday and throughout the week. What has been known...
Published:
Last Updated:
Dell’s (NASDAQ: DELL) margins rushed past expectations and shares moved higher (Reuters) Bernanke said a strong US recovery is essential to global economic health (Reuters) Lawmakers attacked...
Published:
Last Updated: